You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


C4XD signs NRF2 Activator deal with AstraZeneca

C4XD – a company focused on drug discovery – has signed a global licensing agreement with AstraZeneca worth up to $402m for its NRF2 Activator programme.